127 related articles for article (PubMed ID: 38554131)
1. Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
Gabrielson M; Hammarström M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2024 Jul; 155(2):339-351. PubMed ID: 38554131
[TBL] [Abstract][Full Text] [Related]
2. Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.
Gabrielson M; Hammarström M; Bäcklund M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2023 Jun; 152(11):2362-2372. PubMed ID: 36637153
[TBL] [Abstract][Full Text] [Related]
3. Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues.
Gabrielson M; Chiesa F; Paulsson J; Strell C; Behmer C; Rönnow K; Czene K; Östman A; Hall P
Breast Cancer Res Treat; 2016 Jul; 158(2):253-61. PubMed ID: 27349429
[TBL] [Abstract][Full Text] [Related]
4. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
6. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Eriksson M; Eklund M; Borgquist S; Hellgren R; Margolin S; Thoren L; Rosendahl A; Lång K; Tapia J; Bäcklund M; Discacciati A; Crippa A; Gabrielson M; Hammarström M; Wengström Y; Czene K; Hall P
J Clin Oncol; 2021 Jun; 39(17):1899-1908. PubMed ID: 33734864
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
[TBL] [Abstract][Full Text] [Related]
10. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer.
de Souza Sales JF; Cabello C; Alvarenga M; Torresan RZ; Duarte GM
Breast; 2007 Apr; 16(2):197-203. PubMed ID: 17178225
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
[TBL] [Abstract][Full Text] [Related]
12. Effects of low dose tamoxifen on normal breast tissue from premenopausal women.
de Lima GR; Facina G; Shida JY; Chein MB; Tanaka P; Dardes RC; Jordan VC; Gebrim LH
Eur J Cancer; 2003 May; 39(7):891-8. PubMed ID: 12706357
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
[TBL] [Abstract][Full Text] [Related]
14. Association of reproductive history with breast tissue characteristics and receptor status in the normal breast.
Gabrielson M; Chiesa F; Behmer C; Rönnow K; Czene K; Hall P
Breast Cancer Res Treat; 2018 Aug; 170(3):487-497. PubMed ID: 29603032
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and breast density in women at increased risk of breast cancer.
Cuzick J; Warwick J; Pinney E; Warren RM; Duffy SW
J Natl Cancer Inst; 2004 Apr; 96(8):621-8. PubMed ID: 15100340
[TBL] [Abstract][Full Text] [Related]
16. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
17. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Change in Mammographic Density among ER-Positive Breast Cancer Patients Using Tamoxifen.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Bowles EJ; Hoover RN; Glass A; Gierach GL
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):212-6. PubMed ID: 26545407
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Gierach GL
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663687
[TBL] [Abstract][Full Text] [Related]
20. Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?
Karck U; Kommoss F
Eur J Cancer; 2000 Sep; 36 Suppl 4():S45-6. PubMed ID: 11056315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
